Under the assumption that TNBC (represented by the basal-like and claudin-low cell lines) and HER2/luminal breast cancer are separate diseases, we again used unsupervised feature selection of MIB/MS data to identify kinases that distinguish TNBC (basal-like/claudin-low) from HER2/luminal breast cancer [23]. This evidence concerns the gene ERBB2 and breast carcinoma.